EUVIMEDEUVIMED entdecken
Crossref

Primary central nervous system lymphoma: consolidation strategies

Carole Soussain, Andrés J. M. Ferreri

Annals of Lymphoma · 2020

DOI: 10.21037/aol-20-29 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Lymphoma, 2020. Verfasst von Carole Soussain und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To eliminate residual malignant cells and prevent relapse, consolidation treatment remains an essential part of the first-line treatment of patients with primary central nervous system lymphoma. Conventional whole-brain radiotherapy (WBRT) delivering 36–40 Gy was the first and most used consolidation strategy for decades. It is being abandoned because of the overt risk of neurotoxicity while other consolidation strategies have emerged. Reduced-dose WBRT is effective for reducing the risk of relapse in patients with complete response (CR) after induction chemotherapy compared to patients who did not receive consolidation treatment, with an apparent reduced risk of neurotoxicity, which needs to be confirmed in patients over 60 years of age. Preliminary results showed the feasibility of stereotaxic radiotherapy as an alternative to WBRT. Nonmyeloablative chemotherapy, consisting of high doses of etoposide and cytarabine, has shown encouraging therapeutic results in a phase II study, with a high risk of hematologic and infectious toxicity. Thiotepa-based myeloablative chemotherapy followed by autologous stem cell transplantation (ASCT) has been proven feasible and effective in two randomized studies. The optimal consolidative therapy has not yet been defined. However, these different consolidation strategies are available for use in clinical practice, guided by their toxicity profiles and the characteristics of the patients. Fragile patients due to advanced age or relevant comorbidities are hardly eligible for consolidation with myeloablative or nonmyeloablative chemotherapy, and 30–50% of eligible patients do not proceed with consolidation therapy because of induction chemotherapy failure. Ongoing randomized studies comparing nonmyeloablative with myeloablative chemotherapy followed by ASCT will provide additional information to better evaluate the risks and benefits of each procedure. Ongoing and further international studies will hopefully improve the efficacy of induction chemotherapy and enable the identification of prognostic factors at diagnosis and at the end of induction treatment, which will allow clinicians to design and assess risk-driven consolidation strategies.

Zitieren

APA

Soussain, C., & Ferreri, A. J. M. (2020). Primary central nervous system lymphoma: consolidation strategies. Annals of Lymphoma. https://doi.org/10.21037/aol-20-29

Vancouver

Soussain C, Ferreri AJM. Primary central nervous system lymphoma: consolidation strategies. Annals of Lymphoma. 2020. doi:10.21037/aol-20-29

BibTeX
@article{Soussain2020,
  author = {Soussain, Carole and Ferreri, Andrés J. M.},
  title = {Primary central nervous system lymphoma: consolidation strategies},
  journal = {Annals of Lymphoma},
  year = {2020},
  doi = {10.21037/aol-20-29}
}
Kostenlos starten →